# Biostatistics and Data Management

> **NIH NIH P01** · DANA-FARBER CANCER INST · 2024 · $262,678

## Abstract

Project Summary
Allogeneic hematopoietic cell transplantation (HCT) is a long-established therapy for blood malignancies. The
therapeutic benefit and potential cure achieved by HCT is mediated by the graft-vs-leukemia (GVL) effect that is
derived from donor immune system. However, the full recognition of the GVL effect has been hampered by
disease relapse and graft-versus-host disease (GVHD). The overarching objective of the research projects in
this application is to better understand the complex pathophysiology of chronic GVHD, the mechanisms leading
to fibrosis and lung injury, and to develop therapeutics targeting the major pathways leading to the common
clinical manifestations of chronic GVHD. More specifically, Project 1 will identify immune networks that
characterize patients who will develop cGVHD and interrogate mechanisms of response to various treatments
for chronic GVHD; Project 2 will be dedicated to develop into bronchiolitis obliterans and lung fibrosis to identify
new therapeutic agents to treat lung chronic GVHD; and Project 3 will perform a phase II clinical trial of a ROCK2
inhibitor to treat lung cGVHD, identify the cellular target of immunologic attack in bronchiolitis obliterans
syndrome (BOS) using lung organoids, and identify the antigenic determinants of immune attack in BOS. Project
1 involves various translational studies to identify a immunologic signature for cGVHD, Project 2 involves animal
studies and Project 3 involves both a clinical trial as well as translational studies to achieve the overarching goal
of this application. The primary objective of the Biostatistics and Data Management Core (Core 3) is to provide
statistical collaboration for all investigators involved in this Program Project. This includes collaboration with
project investigators in the design of clinical trial and laboratory studies, analysis of clinical and laboratory data
and to establish correlations of clinical outcomes with laboratory results, and participate in manuscript writing in
all Projects. Core 3 will also provide centralized mechanisms to assure the timely and complete capture of all
clinical data in this Program Project. This includes collection and maintenance of necessary clinical information,
data management support, quality control for clinical data, and oversight of clinical trial operations to ensure that
all data elements required by each protocol are collected in timely fashion; and where necessary, design of
research procedures and databases to allow blinded laboratory assessments and later integration with patient-
level data for analysis.

## Key facts

- **NIH application ID:** 10914137
- **Project number:** 5P01HL158505-03
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Haesook T Kim
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $262,678
- **Award type:** 5
- **Project period:** 2022-09-15 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10914137

## Citation

> US National Institutes of Health, RePORTER application 10914137, Biostatistics and Data Management (5P01HL158505-03). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10914137. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*